Outcomes of patients during 77 pregnancies, stratified based on antiphospholipid antibody profile
| LA (+) only* (n=27) | LA (+) with aCL or aβ2GPI (+) (n=21) | aCL and/or aβ2GPI (+) (n=7) | Triple aPL (+) (n=22) | |
| TLD (N: 36) | 11 (41%) | 9 (43%) | 4 (57%) | 12 (55%) |
| PTLD (n=12) | 6 (22%) | 2 (10%) | – | 4 (18%) |
| FD† (n=9) | 4 (15%) | 3 (14%) | 1 (14%) | 1 (5%) |
| EPL (n=20) | 6 (22%) | 7 (33%) | 2 (29%) | 5 (23%) |
| Composite pregnancy morbidity (n=14) | 7 (26%) | 3 (14%) | – | 4 (18%) |
*aCL and aB2GPI not tested in five pregnancies, aB2GPI not tested in four additional pregnancies.
†Two fetal deaths associated with anomalies: 1 triple X syndrome (47 XXX) at 21 weeks, 1 cystic fibrosis at 20 weeks.
aCL, anticardiolipin antibody; aPL, antiphospholipid antibodies; aβ2GPI, anti-β2 glycoprotein-I antibody; EPL, early pregnancy loss; FD, fetal death; LA, lupus anticoagulant; PTLD, preterm live delivery; TLD, term live delivery.